New AI Foundation Model Predicts Drug-Protein Interactions and Designs Novel Therapeutics
Researchers have developed a Specificity Foundation Model (dtSFM) that predicts which drugs bind to which proteins and can identify off-target effects and design new drug candidates directly from molecular sequences. The model was trained on over 714,000 measured drug-protein interactions and validated against AlphaFold 3 structural predictions. The approach could accelerate drug discovery by computationally screening for efficacy and safety before experimental testing.
Scientists have created a machine learning model called the drug-target Specificity Foundation Model (dtSFM) that predicts molecular binding between small-molecule drugs and proteins by treating binding as a thermodynamic quantity computed directly from sequence data. The model was trained on a large public dataset of 714,747 measured interactions between 522,776 compounds and 22,964 proteins. The researchers demonstrated three key applications: identifying off-target effects (ranking known off-targets of kinase inhibitors at the top 0.6% of a proteome-wide screen), repurposing existing drugs for new targets (identifying 46 novel candidates for immunology targets), and generating entirely new drug molecules (with 71% of designed candidates matching the structural quality of approved drugs). The predictions were independently validated using AlphaFold 3, a structural prediction tool with completely different architecture and training data, strengthening confidence in the results. The authors note that experimental laboratory validation is the necessary next step.
What's missing
The study does not discuss computational costs, inference time, or practical implementation timelines for wet-lab validation. The generalizability of the model to non-kinase drug classes and whether performance varies significantly across different protein families or therapeutic areas is not detailed. The paper also does not address how the model handles novel chemical scaffolds or proteins not well-represented in the training data.
What different sources said
- arXiv q-bioCenter
FoldSAE: Learning to Steer Protein Folding Through Sparse Representations
- bioRxivCenter
Promera: a unified model for biomolecular structure prediction, filtering, and design
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.